Company: BDRX
Filing Date: 2025-01-17
Form Type: F-1
Source: 0001214659-25-000922
Chunk: 394

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-17
Form: F-1
Chunk 394
---
 impairment provision of £414,000 in the year to 31 December 2022. As a result of Bioasis’ s announcement on
20 June 2023 the loans have been written off.

| F-53 |

| 14 | Cash and cash equivalents and cash flow supporting notes |

Cash and cash equivalents
for purposes of the consolidated statement of cash flows comprises:

| Schedule of cash and cash equivalents |     |            |     |            |     |            |
|                                       |     | 2023 £’000 |     | 2022 £’000 |     | 2021 £’000 |
| Cash at bank available on demand      |     |      5,971 |     |      2,836 |     |     10,057 |

During 2023, 2022 and
2021, cash inflows arose from equity financing transactions, included within financing activities on the face of the cash flow statement.
As part of the equity transactions entered in December and May 2023 warrants to the value of £4.6million (December 2022:£nil;
July 2021: £nil) were issued as disclosed in note 18.

| Schedule of cash inflows from an equity financing transaction |     |            |   |     |            |   |     |            |   |
|                                                               |     | 2023 £’000 |   |     | 2022 £’000 |   |     | 2021 £’000 |   |
| Gross proceeds                                                |     |     12,084 |   |     |        321 |   |     |     10,091 |   |
| Transaction costs                                             |     |     (1,657 | ) |     |        (78 | ) |     |     (1,056 | ) |
| Proceeds from issuing shares                                  |     |     10,427 |   |     |        243 |   |     |      9,035 |   |

The following changes
in loans and borrowings arose as a result of financing activities during the year:

| Schedule of changes in bank loan liabilities                                                |     |                   |   |     |                   |   |     |             |   |
|                                                                                             |     |       Non-current 
 liabilities £’000 |   |     |           Current 
 liabilities £’000 |   |     | Total £’000 |   |
| At 1 January 2023                                                                           |     |